ALK and cancer: In the era of precision medicine, targeted therapies have caused a revolutionary improvement in cancer management by inhibiting activating genetic alterations in the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS1 proto-oncogene receptor tyrosine kinase (ROS1).